Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
Pre-publication versions of this article are available by contacting email@example.com.
|19 Mar 2018||Submitted||Original manuscript|
|21 Apr 2018||Author responded||Author comments - Rui-Lian Chen|
|Resubmission - Version 2|
|21 Apr 2018||Submitted||Manuscript version 2|
|30 Jul 2018||Reviewed||Reviewer Report - Junling Li|
|16 Aug 2018||Reviewed||Reviewer Report - Reviewer 2|
|16 Sep 2018||Author responded||Author comments - Rui-Lian Chen|
|Resubmission - Version 3|
|16 Sep 2018||Submitted||Manuscript version 3|
|24 Sep 2018||Reviewed||Reviewer Report - Reviewer 2|
|Resubmission - Version 4|
|Submitted||Manuscript version 4|
|12 Nov 2018||Editorially accepted|
|26 Nov 2018||Article published||10.1186/s12885-018-5078-y|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.